Recognized for the Highest Usage and Purchase Volume in Japan, Becoming the Only Clinic in the Country to Receive this Top-Tier Status
IRVINE, Calif. --SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ("SBC Medical" or the "Company"), a Medical Services Organization providing management support across a wide range of healthcare fields, today announced that Shonan Beauty Clinic, to which the Company provides management support, has been awarded the "DIAMOND" certification by PharmaResearch. PharmaResearch is a medical manufacturer based in Gangwon-do, South Korea (CEO: Jihoon Sohn), known for developing the aesthetic healthcare brand "REJURAN." This certification represents the highest tier in the brand's clinic certification system. Shonan Beauty Clinic was recognized for its significant usage and purchase volume, making it the only medical institution in Japan to receive the "DIAMOND" status.
"REJURAN," provided by PharmaResearch, is a brand rooted in regenerative medicine originating from South Korea. It is an injectable treatment designed to promote natural rejuvenation by enhancing the skin's inherent healing capabilities. The brand is widely recognized globally, particularly in Asia, and has earned high acclaim in the aesthetic healthcare field. Shonan Beauty Clinic introduced REJURAN at an early stage and has been providing the procedure to a wide range of customers to encourage skin regeneration. The clinic's delivery system is supported by continuous medical education and comprehensive safety management protocols, which contributed to this exclusive recognition in Japan.
For more information on the REJURAN treatments at Shonan Beauty Clinic, please visit here.
SBC Medical remains committed to strengthening partnerships with advanced medical manufacturers such as PharmaResearch. The Company will continue to contribute to the sound development of the aesthetic healthcare industry while striving to provide optimal medical care tailored to each individual customer.
About PharmaResearch
Headquartered in Gangwon-do, South Korea, PharmaResearch is a leading company in the field of regenerative medicine. The company develops and provides regenerative medical solutions, including polynucleotide (PN) products utilizing patented technology, and distributes a variety of products in the fields of aesthetic healthcare, plastic surgery, and dermatology worldwide. Its flagship brand, "REJURAN," has garnered high acclaim globally, especially in Asia, for its skin repair and regeneration treatments.
Official Website: https://pharmaresearch.com
About SBC Medical Group Holdings Incorporated
SBC Medical Group Holdings Incorporated is a Medical Services Organization providing management support across a wide range of healthcare fields, including advanced aesthetic healthcare, dermatology, orthopedics, fertility treatment, gynecology, dentistry, alopecia treatment (AGA), and ophthalmology. The Company manages a diverse portfolio of clinic brands and is actively expanding its global presence, particularly in the United States and Asia, through both direct operations and medical tourism initiatives. In September 2024, the Company was listed on Nasdaq, and in June 2025, it was selected for inclusion in the Russell 3000® Index, a broad benchmark of the U.S. equity market. Guided by its Group Purpose "Contributing to the well-being of people around the world through medical innovation," SBC Medical Group Holdings Incorporated continues to provide safe, trusted, and high-quality medical services while further strengthening its international reputation for quality and trust in medical care.
For more information, visit https://sbc-holdings.com
For more insights and updates from SBC Medical, follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company's beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company's control. These forward-looking statements reflect the Company's current views with respect to, among other things, the Company's product launch plans and strategies; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," "targets" or "hopes" or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management's current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading "Risk Factors" and elsewhere in the Company's filings with the U.S. Securities and Exchange Commission (the "SEC"), which are accessible on the SEC's website at www.sec.gov.
Contacts
Hikaru Fukui / Head of IR Department; E-mail: ir@sbc-holdings.com
Akiko Wakiyama / Chief Public Relations Officer; E-mail: pr@sbc.or.jp